#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team. In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo #biotechnews #fundraising #venturecapital #oncology #lungdiseases
While the San Diego-based biotech awaits a Phase IIa data readout for its lead lung disease candidate, Endeavor BioMedicines' next-generation HER3-targeted antibody-drug conjugate will start a Phase I/II trial later this year. #biotech #biospace https://hubs.ly/Q02tXR8M0